February 1987

Acute Tumor Lysis Syndrome in Prolymphocytic Leukemia

Author Affiliations

From the Department of Medical Oncology, Roswell Park Memorial Institute, Buffalo.

Arch Intern Med. 1987;147(2):375-376. doi:10.1001/archinte.1987.00370020193063

• Prolymphocytic leukemia is characterized by a low response rate to agents that are effective in the treatment of chronic lymphocytic leukemia. A 75-year-old man with prolymphocytic leukemia was followed up over a period of 69 months. During that time, he was treated with high-dose chlorambucil plus prednisone; cyclophosphamide administered daily; combinations of vincristine sulfate, prednisone, and cyclophosphamide; irradiation to the spleen; and α-interferon without substantial antitumor effect. The patient had a brief response after splenectomy. When he received low-dose vincristine therapy daily with high-dose prednisone therapy given on alternate days, a fatal tumor lysis syndrome occurred. Although rare, this complication should be kept in mind, particularly in patients who had rapid reduction of tumor cells.

(Arch Intern Med 1987;147:375-376)